Browse News
Filter News
Found 8,497 articles
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Initial Therapeutics Names Peter DiLaura as CEO
4/18/2024
Initial Therapeutics Inc. has appointed Peter DiLaura as President and Chief Executive Officer and a member of the company's Board of Directors, effective immediately.
-
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
4/18/2024
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its full-year 2023 financial results for the period ended December 31, 2023 and provided a corporate update.
-
Inflammatory disease–focused Mirador Therapeutics landed the largest early-stage VC investment in biopharma last quarter, as more companies are securing $150 million or more.
-
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
4/17/2024
Windtree Therapeutics, Inc. today reported financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided key business updates.
-
Sensorium Therapeutics Appoints Sam Rasty as Chief Business Officer
4/17/2024
Sensorium Therapeutics today announced the appointment of Sam Rasty, Ph.D., as Chief Business Officer.
-
Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering
4/16/2024
Calidi Biotherapeutics, Inc. today announced the pricing of its “reasonable best efforts” public offering of 15,197,500 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying Series A Common Warrants.
-
GeneVentiv Therapeutics Awarded $2.5 Million SBIR Grant to Advance Gene Therapy for All Hemophilias, with or without Inhibitors
4/16/2024
GeneVentiv Therapeutics, developer of GENV-HEM for all hemophilias, announced it has been awarded a Direct to Phase II Small Business Innovation Research grant for approximately $2,500,000 from the National Heart Lung Blood Institute at the National Institutes of Health.
-
Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules
4/12/2024
Oncocyte Corporation, a precision diagnostics company, announced that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 5,077,387 shares of common stock, at a purchase price of $ 2.9164 per share of common stock, and pre-funded warrants to purchase 342,888 shares of common stock at a purchase price of $2.9163 per pre-funded warrant.
-
Oncocyte Reports Full Year 2023 Financial ResultsConference Call on Friday, April 12, 2024 at 5:00 a.m. PT / 8:00 a.m. ET
4/12/2024
Oncocyte Corporation, a precision diagnostics company, reported financial results for the year ended December 31, 2023.
-
Engineered T Cells Market Size, Growth, Trends and Forecast 2024-2033
4/11/2024
The global engineered T cells market size was estimated at USD 26.87 billion in 2023 and is projected to hit around USD 348.9 billion by 2032, growing at a CAGR of 32.96% from 2023 to 2032.
-
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, Inc.
4/11/2024
ARTMS Inc. (ARTMS) is pleased to announce that the acquisition by Telix Pharmaceuticals Limited (Telix) has been completed.
-
Stamford Pharmaceuticals Inc Announces the First Patient to Be Treated with SP-002 in Combination with Erivedge® in a Phase 2 Study in Locally Advanced BCC Subjects
4/11/2024
Stamford Pharmaceuticals Inc today announced initiation of its locally advanced basal cell carcinoma (laBCC) trial (NCT06344052).
-
Atopic Dermatitis Clinical Trials Market Size to Increase USD 6.81 BN by 2033
4/10/2024
According to Vision Research Reports, the global atopic dermatitis clinical trials market size was accounted at USD 2.37 billion in 2023 and it is expected to increase around USD 6.81 billion by 2033, poised to grow at a CAGR of 11.14% from 2024 to 2033.
-
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
4/10/2024
Nuvation Bio Inc. (NYSE: NUVB) today announced the completion of the acquisition of AnHeart Therapeutics Ltd. (AnHeart), a late-stage, global biopharmaceutical company developing novel precision therapies for people with cancer.
-
A pair of biotechs burst onto the scene Tuesday, exiting stealth with $100 million in financing each and tapping executives who made their names at bluebird bio and Karuna Therapeutics.
-
Seaport Therapeutics Launches with $100 Million Oversubscribed Series A Financing Round to Advance Novel Neuropsychiatric Medicines
4/9/2024
Seaport Therapeutics, a clinical-stage biopharmaceutical company that is charting a proven path in neuropsychiatry, announced the closing of a $100 million oversubscribed Series A financing round.
-
RenovoRx Announces $11.1 Million at Market Private Placement
4/8/2024
RenovoRx, Inc. today announced the execution of definitive subscription agreements with accredited investors for a private placement which is expected to result in gross proceeds of approximately $11.1 million to RenovoRx, before deducting offering expenses.
-
Propanc Biopharma’s CEO Shares Views on Revolutionizing Cancer Treatment: An Inside Look at Drug Development & Strategic Financing
4/8/2024
Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced that the Company’s CEO, Mr. James Nathanielsz, shares his views on revolutionizing cancer treatment with an inside look at drug development and strategic financing.
-
Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement
4/5/2024
Biodesix, Inc. today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock at a price to the public of $1.15 per share. In addition, Biodesix has entered into securities purchase agreements for a concurrent private placement of 760,857 shares of its Series A Non-Voting Convertible Preferred Stock at a price of $46.00 per share.